“The priority objectives over the analyzed period were to increase sales in the market – Antibiotice SA output taken off the market -, indicator which registered a value of RON 73.1 million (EUR 16.4 million), increasing by 7.3 percent compared to the first quarter of 2014, when it amounted to RON 68.1 million (EUR 15.3 million), as well as the sales growth in pharmacies to patients who have evolved by 26.5 percent compared to the same period last year,” reads a press release of Antibiotice quoted by Mediafax.
The company estimates that by diminishing its supplies in the market, there were created the prerequisites for the resumption of the turnover’s upward trend.
The company achieved in the first quarter sales revenues of RON 52.6 million (EUR 11.8 million), down 13 percent.
In the first quarter of 2015, the company launched three products in the cardiovascular class and a product in the anti-infectives for systemic use class.
The export generated increased sales of finished products that were 8 percent higher than in the first quarter of last year.
The company also announced that in Q1 was negotiated a new distribution agreement on the US market, with one of the leading players on the injectables market. This contract will result in commercial deliveries in the second half of 2015.
Also, new collaboration projects were initiated for markets in Europe, the Russian Federation and the CIS area, Southeast Asia and Middle East. (source: business-review.eu)
